Haleon Shares Edge Lower as Weak Cold and Flu Season Weighs on Q1 Sales

Haleon (LON: HLN) posted a modest 2.2% organic revenue growth in the first quarter of 2026, hampered by a softer-than-expected global cold and flu season.

While North America finally returned to growth, the broader respiratory drag has prompted markets to adopt a cautious stance, sending shares slightly lower despite management reiterating full-year guidance.

Reported revenue came in flat at £2.86 billion, translating to a mere 0.1% reported growth year-over-year. Organic growth of 2.2% was driven entirely by a 2.4% pricing increase, which barely offset a slight 0.2% volume contraction.

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG

5.0

View Offers

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

While specific Q1 profit figures were omitted from the trading update, core supply chain productivity initiatives continue to drive gross margin expansion. This operational efficiency supports the reiterated target of high-single-digit adjusted operating profit growth at constant currency for the fiscal year.

Capital allocation remains highly disciplined, with the company progressing steadily on its £500 million share buyback program for 2026.

Haleon’s commitment to shareholder returns remains a bright spot amidst the top-line deceleration. The consumer healthcare giant has already completed approximately 36% of its £500 million share buyback allocation for the year.

This ongoing repurchasing activity provides a vital floor for the stock, signaling management’s confidence in cash generation and long-term value creation even as external macroeconomic headwinds and volume pressures persist.

Driver Breakdown Box:

• Respiratory Drag: A notably weak cold and flu season shaved an estimated 130 basis points off total organic growth, pushing overall Respiratory Health category revenues down 3.4% for the quarter.
• Oral Health Outperformance: Sensodyne and parodontax continue to command strong pricing power and market share. Continuous innovation rollouts across the clinical platform drove an impressive 8.3% organic growth in the Oral Health division.
• North American Recovery: Despite the respiratory headwinds, the critical North American market returned to positive territory with 1.0% organic revenue growth, indicating that broader brand activations and strategic growth initiatives are successfully gaining traction.

AskTraders Takeaway:

The Q1 print paints a picture of a resilient, diversified portfolio masking localized seasonal weakness. Markets are currently fixating on the slight volume contraction and the respiratory segment’s drag on the top line. However, underlying operational leverage remains firmly intact. With gross margins expanding and the foreign exchange translation impact now expected to be broadly neutral for the year, profitability metrics are shielded. Volatility may persist in the near term as markets digest the sluggish volumes, but the reiterated 3-5% full-year organic growth target suggests management anticipates a steeper acceleration in the back half of the year.

CEO Brian McNamara stated, “We delivered a competitive performance in a challenging market, with North America returning to growth and Oral Health again performing strongly… tempered by a weak cold and flu season,” reinforcing the company’s focus on productivity initiatives and geographic expansion to drive agility.

Eyes On: Watch margin expansion closely in the upcoming quarters—if supply chain productivity continues to outpace inflation, it could fuel a sustained rally regardless of seasonal top-line fluctuations.